Open AccessHumoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls
Author(s) -
Freddy Caldera,
Keith L. Knutson,
Sumona Saha,
Arnold Wald,
Hiep Phan,
Kelly Chun,
Ian Grimes,
Megan Lutz,
Mary S. Hayney,
Francis A. Farraye
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000001570
Subject(s) - medicine , immunogenicity , interquartile range , inflammatory bowel disease , antibody , immunology , immune system , gastroenterology , disease
Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs).